Answers are grounded in this paper and cite their sources.
Background: Tirzepatide, a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, has emerged as a potent agent for the management of type 2 diabetes mellitus (T2DM) and obesity. Delayed gastric emptying is a recognised pharmacological effect of incretin-based therapies; however, frank drug-induced gastroparesis with an unusually prolonged clinical course has been infrequently reported for tirzepatide. Case description: We describe a 52-year-old man with T2DM and obesity who developed debilitating nausea, recurrent non-bilious vomiting, early satiety, and an 8-kg weight loss over 4 weeks following escalation of tirzepatide to 10 mg weekly. Mechanical obstruction was excluded by upper gastrointestinal endoscopy, and gastric emptying scintigraphy confirmed markedly delayed solid gastric emptying with 58% meal retention at 4 hours. Tirzepatide was discontinued, and treatment with oral metoclopramide and dietary modification was initiated. Despite cessation of the offending agent, symptomatic and objective resolution did not occur until approximately 9 weeks after discontinuation, suggesting a prolonged neuromotor recovery trajectory beyond standard pharmacokinetic expectations. Conclusion: This case highlights tirzepatide as a cause of clinically significant, potentially long-lasting gastroparesis. Clinicians should recognise that recovery after drug discontinuation may be protracted. Early identification, patient education, and judicious dose escalation are essential safety measures for this increasingly prescribed medication.
No takes yet. Share an insight, caveat, or question.
Diyora et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: